From Yahoo Finance · · 1m 10s
BioCryst Turns First Profit
BioCryst becomes profitable with Orladeyo and plans rare disease acquisitions.
In brief
BioCryst becomes profitable with Orladeyo and plans rare disease acquisitions. BioCryst Pharmaceuticals achieved its first profit from Orladeyo and plans to acquire rare disease treatments using cash from the drug. Originally reported by Yahoo Finance.
BioCryst Turns First Profit
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported consistent profitability on August 28, 2026, from its hereditary angioedema drug Orladeyo.
Orladeyo Generates $645m Sales
Orladeyo is projected to bring up to $645 million in 2026 sales, providing BioCryst with a self-funded growth engine.
Acquired Astria Therapeutics
BioCryst acquired Astria Therapeutics in January 2026, adding navenibart, a late-stage hereditary angioedema candidate.
Navenibart Trial Data Expected 2027
Navenibart completed enrollment in its pivotal trial in June 2026, with data expected in 2027 if the drug succeeds.
Sold European Business for $250m
BioCryst sold its European Orladeyo business to Neopharmed Gentili for $250 million upfront in 2025.
Licensed European Rights for $70m
BioCryst licensed European commercialization rights for navenibart to a Neopharmed affiliate for $70 million upfront, up to $275 million in milestones, and 18-30% royalties.
Financial Risks Remain
BioCryst still faces $822 million in obligations and negative shareholders' equity despite profitability, limiting acquisition flexibility.
The essence
BioCryst Pharmaceuticals achieved its first profit from Orladeyo and plans to acquire rare disease treatments using cash from the drug.
